National guidelines for hiv and aids treatment and care in adolescents and adults

Objectives

Nigeria’s 2010 National Guidelines for HIV and AIDS Treatment and Care in Adolescents and Adults provide the national framework for high-quality, comprehensive, safe and effective HIV treatment and care. The guidelines aim to reduce HIV-related morbidity, mortality and onward transmission, improve quality of life and wellbeing, and maintain treatment efficacy through antiretroviral therapy (ART), prevention, monitoring, care and support.[1][2][3]

• Expand HIV counselling and testing to enable earlier diagnosis, linkage to care, treatment access and prevention of transmission.[4][5]
• Provide ART for eligible adults and adolescents, generally initiating treatment at a CD4 count at or below 350 cells/mm³, for World Health Organization clinical stage 3 or 4 disease, active tuberculosis or specified hepatitis B treatment indications.[2][6]
• Achieve sustained viral suppression, immune restoration, improved quality of life and reduced transmission to infants and sexual partners through combination therapy, adherence support, laboratory assessment, management of opportunistic infections and continuing follow-up.[3][6]
• Use at least three antiretroviral medicines and avoid monotherapy or dual therapy because of resistance risks; phase out stavudine as a preferred medicine because of toxicity concerns.[6][7]
• Provide differentiated regimen options and treatment management for tuberculosis, hepatitis B co-infection, pregnancy, renal impairment, HIV-2 infection, prior prevention-of-mother-to-child-transmission exposure and treatment failure.[7][8][9]
• Promote adherence above 95% where possible, supporting correct medicine-taking, clinic attendance, virological success and prolonged effectiveness of first-line regimens.[10][11]
• Prevent HIV and related infections through post-exposure prophylaxis, isoniazid preventive therapy, cotrimoxazole prophylaxis, prevention of mother-to-child transmission, sexually transmitted infection management and prevention with positives programming.[11][12][13][14]
• Deliver comprehensive care and support that includes nutrition, immunisation, palliative care, psychosocial, spiritual, legal and social support, caregiver assistance, safe water and hygiene, and referral to other services.[15][14][16][17]
• Protect patients and health workers through universal safety precautions, pharmacovigilance, recognition and management of adverse drug reactions, and safe referral arrangements.[18][19][20]

Implementation

Implementation combines nationally led guideline revision and coordination with decentralised clinical delivery, referral networks, patient monitoring and participation by public, private, faith-based, community and international partners. The National Agency for the Control of AIDS coordinates the multisectoral response, while the Federal Ministry of Health’s National HIV/AIDS Division leads development and periodic revision of treatment guidance with expert input and consideration of World Health Organization recommendations.[1][2]

• Use the guidelines as the principal national guide for HIV treatment and care, revising them every two years to reflect developments in treatment and global best practice.[1][2]
• Deliver ART through an increasingly devolved model, expanding provision from tertiary to secondary facilities and using a hub-and-spoke network connecting tertiary, secondary, primary, private and faith-based providers.[2][20][21]
• Allocate specialised laboratory services, viral-load testing and complication management to tertiary centres; provide intermediate diagnostic services, CD4 testing and ART at secondary facilities; and provide counselling, refills, adherence support, simple opportunistic-infection treatment and referral at primary and community-level facilities.[20][21][22]
• Refer people diagnosed in free-standing, mobile or primary facilities for enrolment into care and ART assessment, using standardised referral and tracking tools to reduce loss to follow-up.[4][5][21]
• Offer voluntary, provider-initiated and opt-out HIV testing with counselling, consent except in specified emergency circumstances, confidentiality and post-test referral.[4]
• Conduct pre-treatment assessment of HIV diagnosis, clinical stage, history, examination, laboratory results, immunisation, nutritional and psychosocial status, treatment readiness, adherence planning and weight.[6]
• Agree individual monitoring schedules with patients before and during lifelong care; assess people not yet eligible for ART clinically and by CD4 count every three to six months, increasing frequency as treatment eligibility approaches.[23]
• Monitor people starting ART at baseline and weeks 2, 4, 8 and 12, then at 12- or 24-week intervals as appropriate, including adherence, clinical condition, CD4 counts, haematology, tuberculosis screening and selected renal and liver tests.[23][24]
• Assess virological, immunological and clinical treatment failure, reinforce adherence before changing regimens, investigate interactions and resistance-related factors, and use optimised second-line or salvage regimens where available.[25][26]
• Establish pharmacovigilance procedures in every ART centre, including routine screening for adverse drug reactions, National Agency for Food and Drug Administration and Control case reporting for moderate to life-threatening reactions, and hospital-based pharmacovigilance committees with defined terms of reference.[18][27]
• Engage State AIDS Control Programmes, clinicians, public-health physicians, civil-society organisations, State and Federal Capital Territory coordinators, the United States President’s Emergency Plan for AIDS Relief Nigeria, implementing agencies and the AIDS Prevention Initiative in Nigeria in guideline development and implementation.[2]
• Require participating private providers to register with relevant government agencies, maintain trained staff, accept inspection, provide the minimum care package and use unified monitoring, evaluation, data-collection and reporting arrangements.[28][22]

The guidelines identify clinical monitoring, referral tracking, pharmacovigilance documentation and unified reporting as operational accountability mechanisms, but the supplied material does not specify a complete programme-wide set of quantitative indicators, a consolidated reporting timetable, or a budgeted implementation plan.[24][18][28]

Monitoring & Evaluation

The guidelines set out a clinically focused monitoring and accountability approach for HIV testing, antiretroviral therapy, prevention, care and support. It combines patient-level assessment, laboratory monitoring, pharmacovigilance, referral tracking, clinical registers and unified monitoring and evaluation arrangements for participating providers, but does not establish a comprehensive set of national quantitative indicators or evaluation targets in the supplied material.[15][23][28][22]

• Monitor people receiving antiretroviral therapy through baseline assessment, scheduled follow-up, adherence support, clinical review, laboratory investigations, management of opportunistic infections and assessment of treatment response.[3][23]
• Schedule reviews for people starting highly active antiretroviral therapy at baseline and at weeks 2, 4, 8 and 12, followed by 12- or 24-week intervals depending on the assessment or test required.[23][24]
• Include physical examination, adherence counselling, CD4 cell counts, haemoglobin or packed-cell volume, tuberculosis screening, liver and renal assessments, and HIV-1 RNA testing at baseline and at 24-week intervals, with additional tests when clinically indicated.[24]
• Assess people not yet eligible for antiretroviral therapy clinically and through CD4 cell counts every three to six months, with more frequent assessment as eligibility approaches.[23]
• Assess virological response against expected viral-load suppression below 400 copies/ml by around week 24 and ideally sustained suppression at 50 copies/ml; assess immune recovery through CD4-cell counts, for which an increase of about 50 to 100 cells/µl per year is expected under optimal conditions.[3][6]
• Classify treatment failure as virologic, immunologic or clinical; where possible, repeat viral-load testing after adherence interventions before determining regimen failure.[25]
• Monitor and grade adverse drug reactions using clinical assessment and laboratory measures, with four severity grades ranging from mild to life-threatening to guide interventions.[24][29]
• Repeat laboratory tests after two weeks for Grade I or II abnormalities and after one week for Grade III abnormalities, followed by reassessment; stop antiretroviral therapy and consult an expert for Grade IV abnormalities.[30]
• Report moderate, severe and life-threatening suspected adverse drug reactions through the National Agency for Food and Drug Administration and Control Pharmacovigilance Form, documenting the reaction, intervention, outcome and follow-up.[18][27]
• Establish hospital-based pharmacovigilance committees with defined terms of reference in every antiretroviral therapy centre, supported by standard operating procedures for detecting, evaluating and reporting adverse drug reactions.[27][19]
• Undertake active pharmacovigilance through screening at each visit and documenting suspected reactions, alongside passive surveillance through voluntary reports by healthcare providers.[31]
• Maintain confidentiality in HIV testing records, provide post-test counselling regardless of test result, and refer people diagnosed with HIV for enrolment in care and assessment for antiretroviral therapy.[4]
• Use registers and appointment records for isoniazid preventive therapy, conduct monthly monitoring for tuberculosis symptoms and adverse effects, and review the patient after two years.[13]
• Review adults receiving cotrimoxazole prophylaxis monthly initially and then every three months if treatment is tolerated, with laboratory monitoring every six months or when clinically indicated.[14]
• Use standardised referral and tracking tools to manage patient and sample movement between care levels and reduce loss to follow-up.[21]
• Require participating private-sector providers to use a unified monitoring and evaluation plan, standardised data-collection tools and regular reporting to the national monitoring and evaluation body, while remaining subject to inspection and visitation by appropriate bodies.[28]
• Review the national guidelines every two years to incorporate developments in HIV/AIDS treatment and care and support safe, effective and appropriately regulated antiretroviral therapy.[1]

Costing & Financing

Costing and financing information is limited. The supplied material identifies one source of financial support for revision of the guidelines and notes affordability, medicine availability and treatment costs as practical considerations, but it does not provide a total budget, costed implementation plan, government allocation, funding gap, unit cost, resource-mobilisation target or economic assumption.[2][6][10][11]

• Receive part financial support from the AIDS Prevention Initiative in Nigeria for revision of the National Guidelines for HIV/AIDS Treatment and Care.[2]
• Receive technical support for the revision process from the United States President's Emergency Plan for AIDS Relief Nigeria and its implementing agencies.[2]
• Consider medicine availability, accessibility, affordability, efficacy and ease of administration in selecting antiretroviral treatment recommendations.[6][7]
• Recognise that free provision of medicines is associated with better adherence, while treatment cost is associated with poorer adherence.[11]
• Identify cotrimoxazole prophylaxis and tuberculosis identification and treatment as high-priority interventions partly because of proven cost-effectiveness, without providing numerical estimates.[14]
• Assign health facilities responsibility for materials and equipment needed for universal safety precautions, including soap, water, towels and educational materials, without specifying financing arrangements or amounts.[20]
• Note that third-line and salvage antiretroviral regimens may be unavailable, but do not quantify the related resource constraint.[26]